**Background of PDGFB Antibody**
The platelet-derived growth factor beta (PDGFB) is a key member of the PDGF family, which plays critical roles in cell proliferation, angiogenesis, tissue repair, and embryonic development. PDGFB binds to PDGFR-β receptors, activating downstream signaling pathways (e.g., MAPK, PI3K-AKT) that regulate cell migration, survival, and extracellular matrix remodeling. Dysregulation of PDGFB signaling is implicated in pathologies such as cancer, fibrosis, atherosclerosis, and vascular disorders.
PDGFB antibodies are tools designed to detect, neutralize, or modulate PDGFB activity. In research, they are widely used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study PDGFB expression and localization in tissues or cell lines. Neutralizing antibodies block PDGFB-receptor interactions, enabling functional studies in disease models (e.g., tumor growth, fibrosis). Clinically, PDGFB-targeting therapies, including monoclonal antibodies, have been explored to inhibit pathological angiogenesis or stromal activation in cancers and chronic fibrotic diseases.
PDGFB antibodies also serve as biomarkers in diagnostics, correlating with disease progression or therapeutic response. Challenges include ensuring specificity and minimizing off-target effects. Overall, PDGFB antibodies remain vital for both mechanistic research and developing targeted therapies in PDGFB-driven disorders.